HER - 2/neu in bladder carcinoma

U. Jacobellis, A. Paradiso, S. Tommasi, R. Ricco, A. Napoli, O. Catucci, S. Treffiletti, A. Callea

Research output: Contribution to journalArticlepeer-review


A total of 66 bladder cancer patients were studied to establish if relationships exist between HER-2/neu alteration and pathological stage and grade and to define a subgroup of patients with poor prognosis in terms of time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein over-expression by Southern and Western blot techniques. Results were analysed statistically. 13% cases were amplified and 39% over-expressed. HER- 2/neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and more over- expression than monofocal tumors. Actuarial analyses did not show a significant correlation between HER-2/neu amplification, over-expression and clinical outcome. Clinical assessment of HER-2/neu status showed this gene is not related to tumor relapse, progression or patient survival.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalActa Urologica Italica
Issue number2
Publication statusPublished - 1999


  • Bladder cancer
  • HER-2/neu
  • Oncogene

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'HER - 2/neu in bladder carcinoma'. Together they form a unique fingerprint.

Cite this